Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

US Digestive Health Celebrates the Grand Opening of Relocated Office and Affiliated Endoscopy Center Space in Bensalem

US Digestive Health

US Digestive Health (USDH), the nation’s third largest gastroenterology (GI) practice, celebrated the opening of its relocated office and affiliated endoscopy center on Thursday, December 8 th, at 5:30 PM. Referring physicians and other attendees received guided tours of the facility after a welcoming ceremony, followed by a ribbon cutting. The new office space is located in Bensalem, PA, at 1311 Bristol Pike, Suite 120 and the endoscopy center is conveniently located in Suite 130. USDH is the region’s leading gastroenterology (GI) practice with over 29 locations and over 200 physicians and specialists currently operating throughout southeastern, southwestern, and central Pennsylvania, and most recently Delaware. US Digestive Heath’s unique approach to practice management provides physicians with the security, stability, and support they need without sacrificing clinical autonomy. When providers have the empowering support system they need to succeed, patients have access to easy, convenient, and exceptional gastroenterology care. “Our practice is built entirely around helping our patients be healthy to the core,” said Jerry Tillinger, CEO of US Digestive Health. “Access to more experienced doctors, breakthroughs emerging from research and innovation, along with AI-enabled technologies, that take the gold standard of colonoscopy to The Platinum Standard SM sets us apart and further redefines what is possible in digestive medicine.” The newly opened US Digestive Health office in Bensalem spans nearly 5,000 square feet and features a state-of-the-art, 6,000 square foot endoscopy center in the adjoining suite. “Patients in Bucks County and Northeast Philadelphia can continue to have expanded access to industry-leading, quality gastroenterology care just one mile down the road from our previous location,” said Dr. Tony Rosa of US Digestive Health at Bensalem, formerly called Gastrointestinal Specialists. “Establishing our partnership with US Digestive Health not only puts us in excellent company alongside the region’s top providers, but also widens our breadth of services, allowing us to continue delivering compassionate and life changing medicine.” In July 2022, USDH announced the country’s largest installment of GI Genius™, an artificial intelligence (AI) system for colorectal cancer screening. The intelligent endoscopy module shows 50% reduction in missed colorectal polyps with AI technology versus standard colonoscopy. The launch gave USDH patients throughout southeastern, southwestern, and central Pennsylvania wide-ranging access to innovative technology and its enhanced capability. Those looking to schedule appointments or establish care can do so via the US Digestive Health website which has online and phone resources listed. About US Digestive Health US Digestive Health (USDH) is the leading gastroenterology practice in the Northeast. USDH was formed in 2019 by Amulet Capital Partners, LP ("Amulet"), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. USDH aims to deliver high-value, patient-centric digestive healthcare by bringing new insight into the care, treatment, and prevention of digestive health disorders. USDH consists of 29 locations, 17 ambulatory surgery centers, over 200 GI providers, and more than 950 employees throughout Southeastern, Central, and Southwestern Pennsylvania, and Delaware. Contact Details LevLane Lauren Stralo +1 610-401-4825 lstralo@levlane.com Company Website https://usdigestivehealth.com

December 22, 2022 08:00 AM Eastern Standard Time

US Digestive Health Announces Eight New Physician Hires

US Digestive Health

US Digestive Health (“USDH”), a network of top-rated gastrointestinal (GI) practices managed by US Digestive Health Management (“USDH Management”), a management services organization created to expand access to high-quality, low-cost gastroenterology care, announced the hiring of eight new physicians to its clinical team in 2022. “We are a rapidly expanding organization, and our goal is patient satisfaction,” said Jerry Tillinger, CEO of USDH Management. “We offer a unique business model that is compelling to doctors looking to grow while maintaining clinical independence. We allow our specialists to focus more on clinical matters and less on administrative tasks, encouraging them to stay on the cutting edge of the digestive healthcare field.” The eight new physicians added to the USDH clinical team in 2022 join a thriving practice with over 29 locations and more than 200 physicians and specialists currently operating throughout southeastern, southwestern, and central Pennsylvania, and most recently Delaware. “Our physicians have performed more colonoscopies, diagnosed more colorectal cancer, and saved more lives than any gastroenterology practice in the Northeast,” said Dr. Dale Whitebloom, Chief Medical Officer of USDH. “We’re thrilled to add this group of accomplished physicians to our team so that we may continue to provide easy and convenient access to comprehensive digestive healthcare to more patients.” The group of new physicians joining USDH include: Dr. Hassan Borghei, D.O, Royersford Dr. Ryan Urbas, D.O., Malvern Dr. Heather Jewel Gerst, D.O., Lancaster and Lansdale Dr. Jennifer Schwartz, D.O., Media and Wynnewood Dr. Marc Hopkins, M.D., Lansdale and Flourtown Dr. Justin DeRosa, D.O., Malvern and Media Dr. Brian Karp, M.D., Malvern and Media Dr. Eren Taydas, M.D., Collegeville About US Digestive Health US Digestive Health (USDH) is the leading gastroenterology practice in the Northeast. USDH and USDH Management was formed in 2019 by Amulet Capital Partners, LP ("Amulet"), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. USDH aims to deliver high-value, patient-centric digestive healthcare by bringing new insight into the care, treatment, and prevention of digestive health disorders. USDH consists of 29 locations, 17 ambulatory surgery centers, over 200 GI providers, and more than 950 employees throughout Southeastern, Central, and Southwestern Pennsylvania, and Delaware. About Amulet Capital Partners Amulet Capital Partners is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in healthcare companies. Amulet focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size between $50 million to $150 million. For additional information, please visit www.amuletcapital.com. Contact Details Lauren Stralo +1 610-401-4825 lstralo@levlane.com Company Website https://usdigestivehealth.com

December 22, 2022 08:00 AM Eastern Standard Time

Poolbeg Pharma identifies new RSV drug candidates

Poolbeg Pharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 22, 2022 05:47 AM Eastern Standard Time

Video

Don’t Let RSV, Flu, and Covid-19 Hijack Your Holidays

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/v8cdWdNaAkM RSV, covid and flu are keeping kids out of school—parents out of work and unable to gather with their families. We are in the height of the Holiday travel season with sick children and now, older adults filling hospitals nationwide Flu and RSV usually circulates from late December to mid-February. But this year, an early spike in cases is resulting in markedly higher numbers of infections and hospitalizations. More importantly, RSV infections among young children and now older adults are filling many U.S. hospitals to capacity. On average, RSV leads to 58,000 hospitalizations among children under age 5 and 177,000 hospitalizations among adults 65 and older each year, according to the U.S. Centers for Disease Control and Prevention. To raise awareness about these significant concerns, Dr Emily Volk, President of the College of American Pathologists, conducted a nationwide media tour. Topics that Dr. Volk addressed included: What exactly RSV is and how it spread Why we are seeing a surge in RSV cases How someone can tell the difference between RSV, Flu, and Covid symptoms If families want to travel and be with their families, this holiday season what precautions are needed to do that safely If you want more information on testing, please visit: cdc.gov/rsv cdc.gov/flu/weekly Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 21, 2022 10:09 AM Eastern Standard Time

Video

Keeping the Focus on Kidney Health

YourUpdateTV

The holiday season is underway, and families and friends are gathering together, it is the perfect opportunity to discuss kidney health and create a plan of action. Recently, Susan Quaggin, MD, FASN, President of the American Society of Nephrology (ASN), participated in a nationwide satellite media and radio tour to discuss kidney health and the importance of prevention and early detection. A video accompanying this announcement is available at: https://youtu.be/i5yowghTq0E More than 37 million Americans suffer from chronic kidney conditions and acute diseases that impact virtually every aspect of their lives as well as their families and communities. Kidney diseases are the ninth leading cause of death in the United States, yet 90% of people with kidney diseases are unaware that they are affected. · Prevention and early detection is key to preventing kidney failure o Those that have a family history of kidney disease, diabetes, obesity, or other health issues are at a higher risk of kidney diseases. · Older adults, people with lower incomes, and people who are Black/African American, Hispanic/Latinx, Native/Indigenous American, Native Alaskan, Asian, and Native Hawaiian or other Pacific Islander are also most at risk for kidney diseases and kidney failure. · The American Society of Nephrology is committed to serving ALL people affected by kidney diseases and kidney failure, including our most vulnerable populations. Dialysis, a therapy for those with kidney failure, has a 5-year mortality rate, which is worse than nearly all forms of cancer and requires billions of dollars annually to manage and treat. Research shows that improved treatments to slow or stop the progression of kidney diseases are critically important. We’re United 4 Kidney Health is an awareness-building initiative led by ASN and has identifed four priorities to move the nation forward from kidney diseases and failure to kidney health: 1. INTERVENE EARLIER to prevent, diagnose, coordinate care, and educate. 2. TRANSFORM TRANSPLANT and increase access to donor kidneys. 3. ACCELERATE INNOVATION and expand patient choice. 4. ACHIEVE EQUITY and eliminate disparities. For more information, visit www.asn-online.org. About Dr. Quaggin Susan E. Quaggin, MD, FASN, is the President of the American Society of Nephrology. She hails from Canada and a graduate of the University of Toronto where she completed her residency and served as chief medical resident for the University’s St. Michael’s Hospital. She completed her nephrology fellowship at the University of Toronto and Yale University, where she also undertook research and post-doctoral training. Currently the Charles Horace Mayo Professor of Medicine, Dr. Quaggin is Chief of Nephrology/Hypertension and Director of the Feinberg Cardiovascular and Renal Research Institute at Northwestern University. In addition to her position as President of ASN, Dr. Quaggin has served in many roles at the American Society of Nephrology including: Associate and Deputy Editor for the Journal of the American Society of Nephrology, Chair of Kidney Week’s Program Committee (2013), cabinet member for the ASN Foundation for Kidney Research's Securing the Future Campaign, council liaison for the Diversity and Inclusion Committee and for the Innovation and Discovery Task Force, membership on the Public Policy Board, Education Committee, and Young Investigator Award Selection Committee, the Grants Review Committee, Chair of the Awards Committee and Chair of the Diabetic Kidney Disease Collaborative (DKD-C) Task Force. About ASN Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 132 countries. For more information, visit www.asn-online.org and follow us on Facebook, Twitter, LinkedIn, and Instagram. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 21, 2022 10:04 AM Eastern Standard Time

Video

A.I. Drug Discovery Company Syntekabio (KOSDAQ:226330.KQ) to Explore Partnerships at the J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023

Syntekabio, Inc.

Syntekabio (KOSDAQ:226330.KQ)(226330:KS), a global AI drug discovery and development company, will participate in the 41st annual J.P. Morgan Healthcare (JPM) Conference and Biotech Showcase™ 2023, which will be held concurrently. One of the largest and most informative healthcare investment symposia in the industry, the conference connects industry leaders, investors, emerging fast-growth companies, and tech innovators from around the world. Syntekabio is also open to requests for meetings and presentations via partneringONE® through Biotech Showcase. Details of the events are as follow: WHAT: JPM BIO One-on-One Partnering 2023 WHEN: January 9-12, 2023 WHERE: San Francisco Marriott Marquis (780 Mission Street | San Francisco) WHAT: Biotech Showcase™ 2023 WHEN: January 9-11, 2023; January 18-19, 2023 (Virtual) WHERE: Hilton San Francisco Union Square (333 O'Farrell Street | San Francisco) Venture capitalists invested more than $52 billion globally in therapeutic-based biotech companies from 2019 to 2021. $35 billion of that went into biotech companies with advanced platform technologies that could transform the industry, including emerging start-ups. With the latest launch of STB Cloud, Syntekabio is generating excitement in the drug discovery industry by cutting through vast swaths of data to speed the discovery and development of new drugs. Be sure to find us in San Francisco at the J.P. Morgan Healthcare Conference and Biotech Showcase events. We encourage you to schedule a time to meet with our team to discuss your product development challenges, licensing deals, potential investment, joint ventures and research, and more. For more information, contact our B/D and I/R team led by Ellie Woo at admin@syntekabiousa.com or +1 (212) 371-2544. SyntekaBio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com/eng. Contact Details Syntekabio USA | WMSG Sabina Lee +1 201-408-5342 wgroup@wmedical.org Company Website https://www.syntekabio.com/eng

December 21, 2022 09:27 AM Eastern Standard Time

This Biotech Company is Pursuing Positive Cash Flow In 2023

Agile Therapeutics, Inc.

Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birth control pill every day. Instead, women can apply the patch weekly on their buttocks, lower abdomen, or upper torso, but not their breasts. About 80% choose to adhere it to their buttocks or lower abdomen, according to the company. Additionally, Twirla is the first and only birth control patch that delivers a low dose of estrogen, which puts it in line with many daily low-dose birth control pills. “We think this product can become a market leader,” Agile CEO Al Altomari said during his RHK Disruptive Growth Conference presentation on Dec. 5. Based on Agile’s third-quarter financial results, Twirla may be a viable alternative to other methods of contraception. Between the second and third quarters: Net revenue grew 43%, from $2.1 million in the second quarter to $3 million in the third quarter. Non-GAAP operational expenditures (OPEX) decreased by 19%. Twirla factory sales increased by 54%. The company had $6.1 million cash on hand as of Sept. 30. “Based on performance so far in the fourth quarter, Agile believes revenue will continue to grow and OPEX will continue to be managed at a responsible level,” Altomari said. “We are on a really great growth spurt right now,” Altomari said. “That third quarter was not a fluke. We’re not going back. We expect both the retail and non-retail side to grow.” If Agile can continue to accelerate revenue growth and maintain OPEX consistent with the past two quarters, the company can potentially begin to generate positive cash flow by the end of 2023. Agile has also expressed a desire to acquire or license another commercial women’s health product, which could potentially accelerate the timeline to generating positive cash flow. The Food and Drug Administration (FDA) approved Twirla in 2020, and Agile began selling it in 2021. Most of the company’s sales are through retailers such as CVS Health Corp. (NYSE: CVS), and it’s working on increasing its non-retail partnerships with organizations such as Planned Parenthood in the coming years. Reaching Its Audience Agile has partnered with Afaxys Inc. to help it get Twirla into college and university health centers in addition to Planned Parenthood clinics across the United States. On the retail side, it’s working with the telehealth platform Nurx to make Twirla available to its patients. Many women in Agile’s target market — women ages 18 to 24 — get their prescriptions through telehealth platforms. Nurx medical providers have prescribed contraception to more than 1 million women. “Young women typically don’t want to spend time going to see doctors or to the pharmacy so we prioritized expanding our footprint in telehealth,” Altomari said. Twirla’s connected TV (CTV) commercial is airing in five key states — California, Florida, Texas, New York, and Illinois — where 45% of women in its target demographic live. “We have an approved product that is growing and generating revenue in a multi-billion dollar market,” Altomari said. “Our job now is to continue growing Twirla, achieve positive cash flow, and deliver shareholder value.” Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Matt Riley - Head of Investor Relations & Corporate Communications mriley@agiletherapeutics.com Company Website https://agiletherapeutics.com/

December 21, 2022 09:05 AM Eastern Standard Time

Recent Study from Yale University Highlights the Impact of Food Sensitivities on Health

YourUpdateTV

Unlike a food allergy, which generates an immediate response and can more easily be identified and isolated from your diet (such as a peanut allergy), food sensitivities will produce a delayed reaction, and can be from a multitude of substances. As a result, they are much harder for people to detect. It's vital to know about food sensitivities that may negatively affect your health. Recently, Dr. Wajahat Mehal, Professor of Medicine and Digestive Diseases at Yale University School of Medicine, participated in a nationwide satellite media tour to discuss food sensitivities A video accompanying this announcement is available at: https://youtu.be/f12Cqq2hwsU A recent survey from That’s it. Nutrition shows that 51% of American households are impacted by food allergies or sensitivities. Many health conditions, including being overweight, migraines, rashes, arthritis, fatigue, bloating, gastrointestinal disorders, irritable bowel syndrome (IBS), Crohn’s disease and even certain respiratory conditions and skin disorders are affected by an overlooked or misunderstood food sensitivity. Nonceliac gluten sensitivity is one such example. Researchers at Yale School of Medicine conducted a landmark study showing that patients with IBS who follow individualized diets based on an Alcat food sensitivity blood test experienced significant symptom improvement. State of the art biological testing such as the Alcat test provides a cellular-based lab analysis to evaluate over 450 food substances and additives to determine which foods may be the offenders. Based on these test results a nutritionist can help you develop an individualized eating plan to best support a patient’s health For more information, visit previmedica.com About Dr. Mehal Dr. Mehal graduated from the University of Oxford Medical Sciences Division in 1989. He works in West Haven, CT and 5 other locations and specializes in Gastroenterology. Dr. Mehal is affiliated with Yale-New Haven Hospital Saint Raphael Campus. Dr. Mehal is the Director of the Yale Fatty Liver Disease Program, Yale School of Medicine and developed an integrated NAFLD program encompassing non-invasive diagnostics, staging, nutrition, weight loss medications, HCC screening and tumor board, liver transplantation and bariatric surgery. He is also the Director of the Yale Weight Loss Program, Yale School of Medicine and helped create a new program that brings all non-surgical weight loss components into a single place and include lifestyle/dietary interventions, psychological (Mindfulness training), medications, meal replacement, and endoscopic approaches (gastric balloon). Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 21, 2022 06:09 AM Eastern Standard Time

Video

Goodbody Health "leans up" the business with CBD extraction plant sale

Goodbody Health Ltd

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 21, 2022 05:07 AM Eastern Standard Time

Video

1 ... 178 179 180 181 182 ... 307